10-OXO-10,11-DIHYDRO-5H-DIBENZ[b,f]AZEPINE-5-CARBOXAMIDE IN THE TREATING OF EPILEPSY

ABSTRACT

10-Oxo-10,11-dihydro-5H-dibenz(b,f)azepine-5-carboxamide has a depressant effect on the central nervous system; the compound is the active ingredient of pharmaceutical compositions and is useful for the treatment of psychosomatic disturbances, of epilepsy and of trigeminal neuralgia.

@iiiifi States Patent 1 [111 3,716,640

Schindler Feb 13, 1973 [54] 10-OXO-10,l1-DIHYDRO-5H- [52] IJ S. CL "424/244 DIBENZ[B,F]CARBOXAMIDE IN THE {51] Int. Cl ..A61k 27/00 TR A N 0F EP [58] Field of Search ..424/244 [56] References Cited [75] Inventor: Walter Schindler, Riehen, Basel,

Switzerland FOREIGN PATENTS OR APPLICATIONS 73 Assignee; Corporation, Ardsley, 403,767 6/1966 Switzerland ..200/239 N.Y. Primary ExaminerStan1ey .l. Friedman [22] Flled: Sept- 1971 Attorney-Karl F. Jorda et al. [21] Appl. No.: 182,213

[57] ABSTRACT Dam l0-Oxo-10,l i-dihydro-5H-dibenz[b,f]azepine-S-car- [62] Division of Ser. No. 16,552, March 4, 1970, Pat. No. amid has a d pressant effect on the central ner- 3,642,775. vous system; the compound is the active ingredient of pharmaceutical compositions and is useful for the [30] Foreign A li ti P i it D t treatment of psychosomatic disturbances, of epilepsy March 10, 1969 Switzerland ..3583/69 and of trigeminal neuralgia.

2 Claims, No Drawings 1o-oxo-10,1nnrnvnno-swnmnuzray AZEPlNE-S-CARBOXAMIDE IN THE TREATING or EPILEPSY CROSS-REFERENCE TO RELATED CASE This is a divisional of Ser. No. 16,552, filed Mar. 4, 1970 now US. Pat. No. 3,642,775 issued Feb. l5, 1972.

DETAILED DESCRIPTION The present invention relates to a new azepine derivative, to a process for the production thereof, to medicaments containing the new compound, and to the use thereof.

More particularly, the present invention relates to l-oxo l0,l l-dihydro-5H-dibenz[b, f]azepine-5- carboxamide of formula I,

(l-CH. 0 0

which has been found to possess valuable pharmacological properties and a particularly high therapeutic index. In the case of oral or rectal administration, the compound has a central nervous system depressant action, as can be shown, e.g., in.the observation test.

Upon administration of about 1.5 to about 200 mg/kg, it exhibits anticonvulsive' action, relaxes the central muscular system and inhibits the fighting reaction of mice. These properties, which are determined by selected standard tests [cp. R. Domenjoz and W. Theobald, Arch.Int.Pharmacodyn. 120, 450 (1959) and W. Theobald et al., Arzneimittel-Forsch. I7, 561 (1967], characterize the compound as being suitable for the treatment of psychosomatic disturbances, epilepsy, trigeminal neuralgia and cerebral spasticity.

The compound of formula I is produced, according to the invention, by hydrolysing lO-methoxy-SH- dibenz[b, f]azepine-5-carboxamide of formula II.

follows: IO-methoxy-SH-dibenzlb, flazepine (J.R.GEI- GY A.G., Belgian Pat. No. 597.793) is reacted with phosgene in toluene to give the lO-methoxy-SH- dibenz[b, flazepine-S-carbonyl chloride, which is converted in ethanol with ammonia into the amide.

As mentioned above, the new active substance is administered orally or rectally. The dosage depends on the manner of administration, the species, the age and on the individual condition. In general, the daily dosage of the active substance varies between about 3 mg/kg and about 20 mg/kg for warm-blooded animals. Suitable dosage units such as dragees, tablets or suppositories, preferably contain 30-200 mg of an active substance according to the invention.

Dosage units for oral administration preferably contain, as active substance, between 10 and percent of the compound of formula I. They are produced by combining the active substance with, e.g., solid pulverulent carriers such as lactose, saccharose, sorbital, mannitol; starches such as potato starch, maize starch or amylopectin, also laminaria powder or citrus pulp powder; cellulose derivatives or gelatine, optionally with the addition of lubricants, such as magnesium or calcium stearate or polyethylene glycols, to form tablets or drage cores. The dragee cores are coated, e.g., with concentrated sugar solutions which can also contain, e.g., gum arabic, talcum and/or titanium dioxide, or with a lacquer dissolved in easily volatile organic solvents or mixtures of solvents. Dyestuffs can be added to these coatings, e.g., to distinguish between varying dosages of active substance.

Other suitable dosage units for oral administration are hard gelatine capsules as well as soft closed capsules made from gelatine and a softener, such as glycerin. The hard capsules preferably contain the active substance as a granulate e.g., in admixture with fillers such as maize starch, and/or lubricants such as talcum or magnesium stearate and, optionally, stabilizers such as sodium metabisulphite (Na S O or ascorbic acid. In soft capsules, the active substance is preferably dissolved or suspended in suitable liquids such as liquid polyethylene glycols, whereby stabilizers can also be added.

Suitable dosage units for rectal administration are, e.g., suppositories consisting of a combination of an active substance with a suppository foundation substance. Suitable as a suppository foundation substance are, e.g., natural or synthetic triglycerides, paraffin hydrocarbons, polyethylene glycols or higher alkanols. Also suitable are gelatine rectal capsules consisting of a combination of the active substance and a foundation substance. Suitable as a foundation substance are, e.g., liquid triglycerides, polyethylene glycols orparaffin hydrocarbons.

The following example will serve to further illustrate the production of the new compound of'formula I; The

3 b. 223 g of 10-methoxy-5H-dibenz[b, flazepine (cp. LR. GElGY A.G., Belgian Pat. No. 597.793) in 1.500

ml of abs. toluene are heated, whilst stirring is performed, to 30 A vigorous stream of phosgene is then introduced into the reaction mixture. The internal temperature is raised in the course of 3 hours to 95 and the reaction mixture is then held for one hour at this temperature. The supply of phosgene is then discontinued, the source of heat removed and the excess of phosgene blown out with dry nitrogen. The precipitated reaction product is subsequently filtered with suction. The tiltrate is concentrated by evaporationunder a water-jet vacuum and the residue crystallized from ethanol. A further amount of the reaction product is obtained which, together with the first fraction, is recrystallized from ethanol, whereupon the 10-methoxy-5H-dibenz[ b, f]azepine-5-carbonyl chloride melts at 138; yield 221 g, 77 percent of the theoretical value.

c. 215 g of the carbonyl chloride, produced according to (b), are refluxed in 2,000 ml of ethanol. Dry am- EXAMPLE 2 500.0 g of 10-oxo-10,l 1-dihydro-5H-dibenz[b, f ]azepine-5-carboxamide are mixed with 550.0 g of lactose and 292.0 g of potato starch. The mixture is moistened with an alcoholic solution of 8.0 g of gelatine, granulated through a sieve and dried. 60.0 g of potato starch, 60.0 g of talcum, 10.0 g of magnesium stearate and 20.0 g of highly dispersed silicon dioxide are mixed in, and the mixture pressed into 10.000 tablets each weighing 150 mg and each containing 50 mg of active substance. Optionally, the tablets can be "EX AMFLEE mm A granulate is produced from 1.000 g of 10-oxo- 10,1 1-dihydro-5H-dibenz[b, f ]azepine-5-carboxamide, 379.0 g of lactose and the aqueous solution of 6.0 g of gelatine. After being dried, the granulate is mixed with 10.0 g of colloidal silicon dioxide, 40.0 g of talcum, 60.0 g of potato starch and 5.0 g of magnesium stearate, and the mixture is pressed into 10.000 drag'ee cores. These are afterwards coated with a concentrated syrup made from 533.5 g of crystallized saccharose, 20.0 g of shellac, 75.0 g of gum arabic, 250.0 g of talcum, 20.0 g of colloidal silicon dioxide and 1.5 g of dyestuff, and then dried. Drag'ees, each weighing 240 mg and each containing 100 mg of active substance, are being obtained.

EXAMPLE 4 To produce 1.000 capsules, each containing mg of active substance, 75.0 g of 10-oxo-l0,1 l-dihydro- SH-dibenzbb, f], azepine-Swarboxarhide, are mixed with 198. g of lactose. The mixture 15 evenly moistened with an aqueous solution of 2.0 g of gelatine and'is then granulated througha suitable sieve e.g., Sieve 111 according to Ph.Helv.V). The granulate is mixed with 10.0 g of dried maize starch and 15.0 g of talcum, and the mixture is uniformly filled into 1.000 hard gelatine capsules, size 1 EXAMPLE 5 A suppository foundation mixture is prepared from 10.0 g of 10-oxo-10,1l-dihydro-SH-dibenz [b, f]azepine-5-carboxamide and 158.5 g of adeps solidus, and from this mixture are filled suppositories, each containing 100 mg of active substance.

What is claimed is:

l. A pharmaceutical composition comprising an effective'amount of useful for treating epilepsy 10-oxo- 10,1 l-dihydro-5H-dibenz[b,f]azepine-S-carboxamide, and a pharmaceutically acceptable carrier therefor.

2. The method of treating epilepsy in a mammal, which method comprises administering to said mammal an effective amount of the compound according to claim 1. 

1. A pharmaceutical composition comprising an effective amount of useful for treating epilepsy 10-oxo-10,11-dihydro-5H-dibenz(b, f) azepine-5-carboxamide, and a pharmaceutically acceptable carrier therefor. 